- 40 general care inpatient beds;
- 21 intensive care beds;
- 6 operating rooms; and
- 2 procedure rooms
- In 2010, the Division of Hematology/Oncology, under the direction of Kenneth DeSantes, MD, provided treatment with I-131 Metaiodobenzylguanidine (MIBG) as rescue therapy for four patients with neuroblastoma who had not responded to conventional treatment. MIBG is administered in a special lead-lined room in the AFCH that was constructed specifically for this purpose.
This unique treatment strategy is currently available in only eight hospitals in the United States. In the future, it is expected that MIBG will become part of initial treatment regimens for patients with neuroblastoma.
- We now actively promote and participate in family-centered rounds (FCR) as part of our inpatient care. The practice of FCR, which has received a lot of national attention, is being carefully studied to determine the characteristics of the interaction that are the most helpful to patients and families.
Elizabeth Cox, MD, PhD, is directing several FCR investigations, which are funded by the Arthur Vining Davis Foundation, the Agency for Healthcare Quality and Research, and the National Patient Safety Foundation. This effort dovetails with organizational efforts to increase patient and family satisfaction and patient safety.
- In 2008, Wisconsin became the first state to screen all newborns for Severe Combined Immune Deficiency (SCID), a rare disorder of the immune system. Babies born with SCID, sometimes known as “Bubble Boy Disease,” have a defect in both T-cell and B-cell production. The disorder is severe and usually fatal without early diagnosis and treatment. Until recently, there was no cure for SCID; however, recent advances in bone marrow transplantation have proven very effective if undertaken before the baby is three months of age.
Two infants were recently diagnosed with SCID and treated at the AFCH. One infant underwent bone marrow transplant at 77 days of age and is doing well at home. The second infant, who was found to have a particular enzyme deficiency as the cause of his disorder, is being managed with replacement therapy at home and will be a candidate for gene therapy in the future.
- Megan Moreno, MD, MSEd, MPH, and her research team are studying the use of social networks by teens and young adults. That research has led to several interventions. For example, Dr. Moreno and her team piloted a study that aimed to reduce online risky behavior by generating a single email from a teen’s physician. They also held focus groups with teens and young adults that discuss the online display of health behaviors, and how those displays impact attitudes and actions toward engaging in risky health behavior.